Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel in Treating Older Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the breast~  * Metastatic disease~* Measurable disease by CT scan or MRI~* Requires first-line chemotherapy for metastatic disease~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 70 and over~Sex~* Female~Menopausal status~* Not specified~Performance status~* Meets both of the following criteria:~  * Lawton's Instrumental Activities of Daily Living score ≥ 4~ * Katz's Activities of Daily Living score ≥ 4~Life expectancy~* More than 3 months~Hematopoietic~* Hemoglobin \> 10 g/dL~* Neutrophil count \> 1,500/mm\^3~* Platelet count \> 100,000/mm\^3~Hepatic~* ALT and AST \< 1.5 times normal~* Bilirubin normal~* Alkaline phosphatase \< 2.5 times normal~Renal~* Creatinine clearance \> 30 mL/min~Cardiovascular~* No congestive heart failure~* No unstable angina pectoris~* No myocardial infarction within the past year~* No uncontrolled hypertension~* No high-risk uncontrolled arrhythmias~Other~* Geriatric Depression Score \< 12~* No active uncontrolled infection~* No active peptic ulcer~* No uncontrolled diabetes mellitus~* No inflammatory bowel disease~* No history of hypersensitivity to docetaxel or drugs formulated with polysorbate 80~* No history of significant neurologic or psychiatric disorders, including psychotic disorders, dementia, or seizures, that would preclude giving informed consent~* No familial, social, geographical, or psychological condition that would preclude study follow-up~* No definite contraindication to corticosteroids~* No other serious illness or medical condition~* No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior or concurrent trastuzumab (Herceptin\^®)~Chemotherapy~* Prior neoadjuvant or adjuvant chemotherapy for breast cancer allowed~* More than 2 years since prior docetaxel or paclitaxel~* No other concurrent chemotherapy~Endocrine therapy~* No more than 1 prior hormonal therapy regimen for metastatic disease~* At least 10 days since prior hormonal therapy~* No concurrent hormonal therapy~* No concurrent chronic corticosteroids~  * Concurrent low-dose corticosteroids (≤ 20 mg/day of methylprednisolone or equivalent) allowed provided treatment was initiated \> 6 months before study entry~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* More than 30 days since prior active treatment on another clinical trial~* Concurrent bisphosphonates allowed for bone metastases, osteoporosis, or osteopenia~* No other concurrent anticancer therapy~* No other concurrent investigational drugs

- Gender: FEMALE
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues